Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 4/20 | 0.51 |
| ▸ | TNKS | O95271 | 3/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | GUSB | P08236 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14579767 | 0.89 | MAP4K4 (0.47) | AURKAMEN1KMT2APARP1NPC1 | |
| SCHEMBL27196551 | 0.86 | AURKA (0.58) | AURKAPARP1NOX1MAPK13RAF1 | |
| SCHEMBL2062423 | 0.85 | TNKS (0.49) | PARP1TNKSTNKS2NPC1NOX1 | |
| SCHEMBL29922981 | 0.84 | MAP4K4 (0.50) | MEN1KMT2APARP1TNKSTNKS2 | |
| SCHEMBL28647943 | 0.84 | MAP4K4 (0.50) | MEN1KMT2APARP1TNKSTNKS2 | |
| SCHEMBL5323937 | 0.84 | MAP4K4 (0.52) | MEN1KMT2APARP1TNKSTNKS2 | |
| SCHEMBL30171053 | 0.84 | MAP4K4 (0.52) | MEN1KMT2APARP1TNKSTNKS2 | |
| SCHEMBL12676130 | 0.82 | PARP1 (0.49) | MEN1KMT2APARP1TNKSTNKS2 | |
| SCHEMBL18574377 | 0.82 | TNKS (0.48) | MEN1KMT2APARP1TNKSTNKS2 | |
| SCHEMBL21180306 | 0.82 | ADORA3 (0.51) | AURKAMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124514-A1 | DEOXYNUCLEOSIDE MODIFIED RUTHENIUM COMPLEX, AND PREPARATION METHOD AND USE THEREOF | Guangzhou Ruby Biotechnology Co., Ltd. (CN) | 2024-04-18 | — | — | US | disclosed |
| US-10358455-B2 | Arene ruthenium complex, preparation method and utilization thereof | GUANGDONG PHARMACEUTICAL UNIVERSITY (CN) | 2019-07-23 | — | — | US | disclosed |
| WO-2007006026-A1 | COMPOSITIONS AND USE THEREOF IN DYE SENSITIZED SOLAR CELLS | GENERAL ELECTRIC COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070000539-A1 | Compositions and use thereof in dye sensitized solar cells | GENERAL ELECTRIC COMPANY | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358455-B2 | Arene ruthenium complex, preparation method and utilization thereof | CBR3, CBR1, C1R | AURKA 3231/4885MEN1 4415/4885KMT2A 4363/4885 |
| US-20240124514-A1 | DEOXYNUCLEOSIDE MODIFIED RUTHENIUM COMPLEX, AND PREPARATION METHOD AND USE THEREOF | RRM2B, RRM2, NCL | AURKA 3963/4885MEN1 3449/4885KMT2A 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.